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Summary 
Conjoint analysis and contingent valuation were used as complementary methods to 
assess potential demand for two vaccine products against East Coast fever, one an 
existing live vaccine and the other a sub-unit vaccine under development.  Both 
approaches were administered to sample farmers in areas in Kenya where the vaccine 
has not yet been introduced.  Conjoint analysis evaluated farmer preferences for key 
vaccine attributes, while contingent valuation assessed farmer willingness to pay to 
the two products.  Both approaches confirm high potential demand for either vaccine. 
 
Introduction 
East Coast fever (ECF) is a tick-borne disease responsible for approximately half of 
cattle mortality in Kenya.  Improved breeds of cattle, especially the higher-value 
animals kept by smallholder farmers for dairy production, are particularly susceptible 
to the disease.  Farmers currently depend on tick control measures to reduce the risk 
of exposing their cattle to the disease, or treating the disease with curative drugs if the 
symptoms are diagnosed in time.  Vaccines have not been available to cattle keepers, 
but this is expected to change in the near to medium future.  A live vaccine, referred 
to as the Infection and Treatment Method (ITM), was developed in the 1970s, but its 
use has been limited to the Kenya Coast.  It is now slated for wider distribution to 
other areas of the country where the great majority of dairy farmers are located.  
Though proven effective, ITM is relatively expensive (US$8-$20/dose) and requires a 
strict cold chain to ensure its viability.  A potentially cheaper and easier-to-deliver 
sub-unit vaccine is also under development at ILRI, but is not expected to be 
available as a commercial product before 2009.  In this paper, we describe economic 
analyses to evaluate the potential farmer demand for these two vaccine products, 
using two different approaches. 
 
Methods 
Conjoint analysis:  The first analysis examines farmers’ preferences for vaccine 
attributes.  Given that ECF vaccines will be distributed as commercial products, their 
eventual success and uptake will depend on how their attributes are perceived and 
judged by cattle keepers.  To gain insight into the relative importance of such vaccine 
attributes, a conjoint analysis experiment was designed to evaluate the role that a few 
key attributes play in decision-making by smallholder dairy farmers when purchasing 
an ECF vaccine.  The selected attributes included: (1) level of expected protection 
(high-95% versus moderate-75%); (2) required frequency of administration (one time 
only versus repeated boosters); (3) risk of reactors (none versus some); and (4) price 
(three different price levels).  Farmers were then presented with a series of 8 cards, 
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each representing a unique combination of one level per attribute, and were asked to 
rank the cards in order of preference.  A fractional factorial design was used to 
identify an orthogonal subset of 8 combinations out of the 24 possible combinations.  
One card, for example, might offer a vaccine at a moderate price providing moderate 
protection, but administered only once and have no risk of reactors.  The attributes 
were represented by picture illustrations as well as text, and the enumerators provided 
a standardized explanation. 
Contingent valuation:  The second analysis evaluates farmer willingness to pay for 
the two vaccine products.  A contingent valuation experiment was designed for each 
type of vaccine and one of the two experiments was randomly assigned to each 
sample household.  After a carefully prepared, standardized explanation of the 
vaccine product, the respondent was presented with one of five possible price bids 
randomly assigned to her, and asked if she would be willing to buy the product.  If 
“yes”, then a second higher price would be proposed, and if “no”, a second lower 
price would be proposed.  The design permitted econometric estimation of a double-
bounded contingent valuation model, using both restricted and unrestricted parametric 
and non-parametric configurations (i.e., with and without covariates). 
Data collection:  Data for the analyses were collected from a sample of 1000 dairy 
farm households in four sites (Makuyu, Kiambu, Uasin Gishu, Kakamega), areas of 
relatively high ECF challenge in the Central and Western Highlands of Kenya, in 
November 2000 to June 2001.  A stratified sampling strategy was applied, with 5 of 
the 10-15 administrative sub-locations in each site first being selected using a 
standard random sampling procedure.  A sampling frame of all cattle-keeping 
households was established for the 5 sub-locations, and 50 households were then 
randomly selected from each sub-location.  Enumerators administered a questionnaire 
and the conjoint analysis experiment during a single visit to each household. 
 
Results and Discussion 
Conjoint analysis:  The conjoint analysis experiment was successfully completed with 
971 farm households.  The results are summarized in Table 1.  Part-worth Scores 
represent an internally consistent utility value of the individual attribute levels. The 
estimated Part-worth Scores all perform to expectations, with price, for example, 
offering increasingly negative utility as the price increases.  Although scores for 
individual attributes varied significantly across the four study sites (p=0.000), the 
general pattern and order of importance were the same. 
Summing the Part-worth Scores for attribute levels associated with a given 
product provides a measure of its perceived utility to farmers.  The current live 
vaccine offers utility of +0.59 (high effectiveness, one-time administration, high 
price, risk of reactors).  The proposed sub-unit vaccine is expected to offer utility of 
+0.90 (high effectiveness, boosters, low price, no reactors), and so should be a more 
attractive product to farmers.  If, however, the sub-unit vaccine is not able to achieve 
as high protection, the utility drops to –2.08; if not sufficiently effective, the sub-unit 
vaccine may be unable to compete successfully with the existing live vaccine, ITM, 
even though ITM is more expensive. 
Proceedings of the 10th International Symposium on Veterinary Epidemiology and Economics, 2003
Available at www.sciquest.org.nz
 3
 Table 1: Conjoint analysis results for farmer preferences for ECF vaccine 
attributes (n=971) 






38.8 % Moderate  (75%) -1.41 
  High  (95%)  1.41 
Frequency of 
administration 
27.5 % Once only  0.95 
  Annual boosters -0.95 
Price 12.3 % KSh 600 -0.33 
    ($US 1=78 KSh)  KSh 1200 -0.66 
  KSh 1800 -1.00 
Safety (risk of reactors) 21.4 % No reactors  0.77 
  5% risk of reactors -0.77 
 
This result is also reflected in the average Relative Importance Scores, representing 
the relative importance of the attribute in percentage terms in the farmer’s overall 
decision-making (with the importance scores for the four attributes summing to 
100%).  The estimated Relative Importance Scores indicate that farmers give highest 
priority to a vaccine that ensures a high level of protection (39% of the overall 
decision), and secondly to one that does not require boosters (28%).  Price is the least 
important factor (12%). 
Contingent valuation:  Data for the contingent valuation experiment have been 
analysed for the Makuyu site only, representing 234 respondents--119 for ITM and 
115 for the proposed sub-unit vaccine product.  The mean willingness to pay 
estimates for ITM ranged between $16.83-$18.33 (US$1=78 KSh) across the various 
models, and for the sub-unit vaccine, between $17.37-$18.83.  Although the 
willingness to pay for the sub-unit vaccine was slightly higher than that for ITM, the 
difference was not statistically significant.  Both sets of estimates exceeded the 
expected farm-gate price of $10-$15 for the more expensive product (ITM).  
 
Conclusion 
Two approaches were applied to assessing farmer demand for two ECF vaccine 
products in areas where a vaccine product has not been available.  In the first 
approach, an indirect method is used in which farmer preferences for specific 
attributes of the vaccine products are evaluated using conjoint analysis.  In the second 
approach, a more direct method of soliciting willingness to pay using contingent 
valuation was attempted.  With respect to price, the two approaches generated 
consistent results, suggesting that even relatively high prices are unlikely to 
discourage farmer uptake of a vaccine.  The analysis of preferences also sends a clear 
signal to developers of the sub-unit vaccine highlighting the critical importance of 
achieving a product that guarantees a sufficiently high level of protection from ECF if 
it is to offer a viable alternative to the existing live vaccine. 
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